Our findings confirmed that CG-806 is a pan-FLT3 inhibitor that may benefit from the simultaneous suppression of FLT3, BTK and AURK activation, leading to a promising anti-leukemia effect against AML regardless of their FLT3 status. The gene discussed is BTK; the disease is leukemia.